Bulk Drug Parks

1. At a Glance

• Centrally Sponsored Scheme by the Department of Pharmaceuticals (DoP), Ministry of Chemicals & Fertilizers, to set up 3 mega Bulk Drug Parks with shared world-class infrastructure to reduce manufacturing cost of APIs/KSMs/Drug Intermediates [S1][S2].
• Strategic goal: cut import dependence (mainly on China) for bulk drugs that form the active ingredient of formulations, advancing Atmanirbhar Bharat in pharma [S3].
• Outlay: ₹3,000 crore (FY 2020-21 to FY 2024-25); Central grant capped at ₹1,000 crore/park [S1][S4].

2. Why in the News

• PIB (13 Feb 2026): DoP clarified Bulk Drug Parks are NOT under the PLI scheme but under a separate scheme; three parks in Andhra Pradesh, Gujarat, Himachal Pradesh are at various stages of development; total project cost ₹6,306.68 crore, Central assistance ₹1,000 crore each [S4].
• Union Budget FY 2026-27 flagged Chemical/Bulk Drug Parks for continued support [S5].

3. Background & Evolution

• March 2020: Union Cabinet approved the Scheme for Promotion of Bulk Drug Parks (notified 2020) — triggered by COVID-19 exposure of API import vulnerability [S1][S2].
• Launched alongside complementary PLI Scheme for KSMs/DI/APIs (₹6,940 crore) by then Union Minister D.V. Sadananda Gowda [S6].
• Sept 2022: 'In-principle' approval to Himachal Pradesh, Gujarat, Andhra Pradesh [S2].
• Predecessor context: India imports ~60–70% of bulk drugs (largely China); 2020 KSM/API scheme + Bulk Drug Park scheme = twin pillars [S3].

4. Core Static Facts

• Nodal Ministry: Ministry of Chemicals & Fertilizers; Department: Department of Pharmaceuticals [S4].
• Scheme Type: Central Sector Scheme (Grants-in-Aid to States) [S1].
• Outlay: ₹3,000 crore [S1][S4].
• No. of Parks: 3 [S1].
• Central Assistance: 70% of CIF project cost (general States); 90% for Hilly/NE States; cap ₹1,000 cr/park [S2].
• Approved States & Sites:
• Himachal Pradesh — 1,402.44 acres, Haroli tehsil, Una district [S2].
• Gujarat — 2,015.02 acres, Jambusar tehsil, Bharuch district [S2].
• Andhra Pradesh — 2,000.45 acres, K.P. Puram & Kodhada, Thondangi Mandal, East Godavari [S2].
• Total project cost (3 parks): ₹6,306.68 crore [S4].
• Common Infrastructure Facilities (CIF): CETP, solid waste mgmt, storm-water drains, solvent storage/recovery, common warehouse, dedicated power sub-station, water (raw/potable/DM), steam, cooling, logistics, advanced testing lab, emergency response, safety audits centre, Centre of Excellence [S1].
• Implementation: Through State Implementing Agencies (SIAs) — utilities provided at subsidised rates [S4].

5. Multi-Dimensional Analysis

Economic - Reduces input cost of APIs via shared infra → lifts price-competitiveness of Indian formulations exports (~$25 bn industry) [S1][S3]. - Attracts large investment; complements ₹6,940 cr PLI for 41 critical KSMs/DI/APIs [S6].

Strategic / Geopolitical - Reduces ~60–70% import dependence on China for bulk drugs — supply-chain de-risking post-COVID [S3].

Environmental - Mandatory CETP, solvent recovery, solid waste & hazardous ops audits centralise pollution control for a notoriously polluting sector [S1]. - Risk: clustering hazardous units (e.g., Bharuch) increases localised environmental load — needs strict zero-liquid-discharge norms.

Administrative / Federal - Centre–State partnership model: Centre funds CIF; State arranges land, clearances, off-site utilities via SIA [S1][S4]. - Three-State selection through competitive challenge method (ranking-based) [S2].

Scientific / Technological - Promotes domestic manufacturing of fermentation-based and chemical-synthesis-based KSMs (e.g., Penicillin-G, 7-ACA) where India lost capacity [S3].

6. Recent Developments (last 12-18 months)

• 13 Feb 2026 (PIB): Reiterated Bulk Drug Parks are separate from PLI; ₹6,306.68 cr project cost; Central aid ₹1,000 cr × 3 [S4].
• Budget FY 2026-27: Continued Chemical Parks push [S5].
• Parks at "various stages of development" — implementation through SIAs ongoing in AP, Gujarat, HP [S4].

7. Prelims Hooks

• Scheme nodal department: Department of Pharmaceuticals (NOT Dept. of Chemicals & Petrochemicals) [S4].
• Parent ministry: Ministry of Chemicals & Fertilizers [S4].
• Total outlay: ₹3,000 crore [S1].
• Number of Bulk Drug Parks: 3 [S1].
• Max Central grant per park: ₹1,000 crore [S1].
• Funding ratio: 70% of CIF (general), 90% for Himalayan/NE States [S2].
• States selected: Andhra Pradesh, Gujarat, Himachal Pradesh [S2].
• AP site: East Godavari district [S2].
• Gujarat site: Bharuch district (Jambusar) [S2].
• HP site: Una district (Haroli) [S2].
• Cabinet approval: March 2020 [S1].
• Scheme is NOT part of PLI; separate scheme [S4].
• Total project cost of 3 parks: ₹6,306.68 crore [S4].
• Targets: KSMs, Drug Intermediates, APIs (bulk drugs) [S3].

8. Mains Relevance

• GS-III: Indian Economy → Industrial Policy; Government schemes for growth; Inclusive growth & infrastructure.
• GS-II: Government policies/interventions for development in health sector.
• Possible question stems: 1. "Reducing India's import dependence for bulk drugs requires more than fiscal incentives." Critically examine in light of the Bulk Drug Parks scheme and PLI for APIs. 2. "Cluster-based manufacturing is the dominant model for India's pharma self-reliance push." Discuss with reference to Bulk Drug Parks. 3. Discuss the environmental and federal challenges in operationalising Bulk Drug Parks.

9. Related Topics to Study Next

• PLI Scheme for Bulk Drugs (KSMs/DI/APIs) — twin pillar with Bulk Drug Parks [S6].
• PLI for Pharmaceuticals — covers formulations & complex generics.
• Medical Devices Parks Scheme — parallel cluster scheme by DoP [S6].
• National Pharmaceutical Pricing Authority (NPPA) — affordability angle.
• Jan Aushadhi (PMBJP) — downstream affordability.
• Atmanirbhar Bharat Abhiyan — supply-chain self-reliance umbrella.
• India–China trade dependence — strategic context.
• CETP/Zero Liquid Discharge norms — environmental angle for pharma clusters.

10. Common Errors / Trap Areas

• Wrong scheme family: Bulk Drug Parks is a stand-alone Central Sector scheme, not a PLI scheme — explicitly clarified by DoP [S4].
• Confusing with PLI for APIs: That is a separate ₹6,940 cr scheme covering 41 products [S6].
• State list: Often wrongly recalled as Telangana/Karnataka — correct list is AP, Gujarat, HP [S2].
• Funding cap: ₹1,000 cr is the ceiling per park, not per State annually [S1].
• 90% funding applies only to Himalayan/NE States (HP qualifies); not to AP/Gujarat [S2].
• District for AP: now part of Kakinada district after AP's 2022 re-organisation, but PIB still references East Godavari — note both [S2].

11. Sources

• [S1] Bulk Drug Park Scheme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2224376 — (tier: 1)
• [S2] Centre Grants 'in-Principle' Approval of three Bulk Drug Parks to Himachal Pradesh, Gujarat and Andhra Pradesh — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=1856080 — (tier: 1)
• [S3] Self-reliance in APIs — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237413 — (tier: 1)
• [S4] Bulk Drug Parks (13 Feb 2026) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2227631 — (tier: 1)
• [S5] Union Budget FY 2026-27: Chemical Parks — https://static.pib.gov.in/WriteReadData/specificdocs/documents/2026/feb/doc202624779601.pdf — (tier: 1)
• [S6] Shri Sadananda Gowda launches Schemes…Bulk Drugs Parks & Medical Devices Parks — https://www.pib.gov.in/PressReleasePage.aspx?PRID=1641517 — (tier: 1)